Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study

(2017) R. J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab

(2017) D. R. Shepard et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on Cardiac Toxicity With Trastuzumab and Radiotherapy: The Question Is Still Ongoing

(2009) Nicolas Magné et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

(2009) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY